Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma
The overall survival in the LT with ADV-TK gene therapy group was 54.8 % at three years, and
the recurrence-free survival in the same group was 56.5 %, both being higher than those in
the transplantation only group (P=0.0001 for overall survival and P=0.0000 for
recurrence-free survival). In no-vascular invasion subgroup treated with LT with ADV-TK
therapy, both overall survival and recurrence-free survival were 100 %, significantly higher
than those with vascular invasion subgroup treated with the combined LT and ADV-TK therapy
(P=0 for each group). Vascular invasion was an important factor affected survival and
recurrence, hazard ratio=3.687; P=0.014 and hazard ratio=12.961; P=0.000, respectively.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival rate at one year
Ding Ma, M.D.
Study Chair
Cancer Biology Research Center, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R.China
China: Ministry of Health
LT2000-09
NCT00300521
September 2000
November 2005
Name | Location |
---|